Trial Profile

A Phase 1 Study of FT-7051 in Men With Metastatic Castration-Resistant Prostate Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 17 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pocenbrodib (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; First in man
Acronyms The Courage study
Sponsors FORMA Therapeutics; Novo Nordisk

Most Recent Events

02 Mar 2023 Status changed from recruiting to discontinued.
05 Aug 2022 According to a FORMA Therapeutics media release, the company is planning to evaluate an alternative dosing schedule in a less heavily pretreated population and is currently processing the protocol amendment and the company plans to provide updated results in the first half of 2023.
26 May 2022 According to a FORMA Therapeutics media release, as of May 12, 2022, 25 patients have been enrolled in this study. Updated data rom this study is expected in the first half of 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com